Search Clinical Trials in the European Union

Duration
Visits
Efficacy phase (II)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
421-440 of 1,738 trials

Parkinson’s Disease vs. Multiple System Atrophy: Imaging Study

We are comparing two imaging methods to see which one better identifies Parkinson’s disease and multiple system atrophy. This may help improve diagnosis for patients with these conditions.

Parkinson's DiseaseAlzheimer's DiseaseMultiple Systems Atrophy - Parkinsonian Variant>2 yearsEfficacy phase (II)Confirmation phase (III)NeurologyOtolaryngology

Fasudil for Early Alzheimer's Disease

We are studying whether fasudil can help prevent memory loss in people with early Alzheimer's disease. The trial will also assess its safety and effects on brain health.

Alzheimer's DiseaseCognitive ImpairmentEfficacy phase (II)6-10 visitsInvestigational MedicinesPartially RemoteNeurologyPsychiatry

Colorectal Cancer: Amivantamab Treatment Study

We are studying the effects of amivantamab alone and with standard chemotherapy for patients with advanced colorectal cancer. The goal is to see how well it works and to ensure it is safe.

Advanced or Metastatic Colorectal CancerSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

Parkinson's Disease: AAV2-GDNF Treatment Study

We are studying a new therapy to see if it can improve motor symptoms in adults with moderate Parkinson's Disease. The trial also looks at safety and overall quality of life for participants.

Parkinson's Disease>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesNeurology

Atopic Dermatitis: Long-Term Study of Amlitelimab

We are evaluating the long-term safety and effectiveness of amlitelimab for individuals with moderate to severe atopic dermatitis who have participated in earlier studies. This research aims to better understand how the treatment works over time.

Atopic Dermatitis>2 yearsEfficacy phase (II)Confirmation phase (III)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyDermatology

Propranolol for Anxiety in Pancreatic Cancer Surgery

We are studying whether propranolol can help reduce anxiety in patients undergoing surgery for pancreatic cancer and if it affects tumor-related changes. This trial will compare the effects of propranolol to a placebo in a small group of participants.

Pancreatic Cancer>2 yearsEfficacy phase (II)Standard MedicinesGastroenterologyInternal MedicineOncology

Mycobacterium abscessus: Optimizing Lung Disease Treatment

We are studying the best treatment options for lung disease caused by Mycobacterium abscessus. Our goal is to see how well these treatments clear the infection and how well patients tolerate them.

Mycobacterium Abscessus Infection1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteInfectious DiseasesPulmonology

Large-Cell Neuroendocrine Carcinomas: Durvalumab Combination Therapy

We are studying a new treatment combining durvalumab with etoposide and platinum for patients with advanced large-cell neuroendocrine carcinomas of the lung. The goal is to evaluate its effectiveness and safety compared to standard treatments.

Large-Cell Neuroendocrine Carcinoma of the LungLocally Advanced or Metastatic Lung Cancer6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesOncologyPulmonology

Alzheimer's Disease in Down Syndrome: Sleep and Temperature Study

We are examining how sleep disorders and body temperature changes may indicate the progression of Alzheimer's disease in people with Down syndrome. This research could help identify early signs of the disease.

Down SyndromeAlzheimer's Disease>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementNeurologyPsychiatry

Niraparib: Long-Term Safety Study for Cancer Patients

We are evaluating the long-term safety and tolerability of niraparib for patients who have previously completed a study and are deemed to benefit from continued treatment. This study helps us understand how well the medication can be tolerated over time.

Advanced Ovarian, Breast, or Prostate CancerEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteOncology

Giant Cell Arteritis: Etanercept vs. Methotrexate

We are comparing two treatments, etanercept and methotrexate, to see which is more effective for patients with giant cell arteritis. The goal is to find out which treatment helps achieve remission and prevents complications better.

Giant Cell ArteritisEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesInfectious DiseasesRheumatology

Crohn's Disease: Dual Biological Therapy Study

We are evaluating whether a combination of medications can help patients with Crohn's disease who haven't responded to previous treatments. The study compares single therapies to combination therapies to find the most effective approach.

Crohn's DiseaseEfficacy phase (II)No PlaceboStandard MedicinesGastroenterologyInfectious Diseases

Ulcerative Colitis: Dual Therapy Study

We are comparing single and combination therapies for patients with ulcerative colitis who didn't respond to previous treatment. The goal is to see which option may help achieve better remission and quality of life.

Ulcerative Colitis>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesGastroenterologyInternal Medicine

Pulmonary Sarcoidosis: OATD-01 Treatment Study

We are studying the effects of OATD-01, an oral medication, on reducing lung inflammation in people with active pulmonary sarcoidosis. The trial will also look at safety, lung function, and quality of life.

Pulmonary Sarcoidosis3-6 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicinePulmonology

Graft-Versus-Host Disease Prevention in Elderly Cancer Patients

We are studying whether a low dose of a specific medication can help prevent complications in elderly patients with blood cancers receiving stem cell transplants. This trial aims to improve recovery and overall outcomes after the transplant.

Blood Cancers>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Non-Hodgkin Lymphoma: BMS-986458 Treatment Study

We are testing a new drug, BMS-986458, for people with relapsed or refractory non-Hodgkin lymphoma. The study aims to understand its safety and how it works alone and with other treatments.

Non-Hodgkin Lymphoma>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

HER2-Positive Gastric Cancer: New Treatment Study

We are testing a new combination of medications for patients with HER2-positive gastric or gastroesophageal cancer. The goal is to see if it helps clear cancer markers and improves survival compared to standard chemotherapy.

Gastric or Gastroesophageal Cancer>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesGastroenterologyOncology

Idiopathic Hypersomnia: Melatonin and Light Therapy Study

We are investigating whether a combination of evening melatonin and morning light therapy can help adults with idiopathic hypersomnia feel less sleepy. This study compares the treatment to a placebo to see if it makes a difference.

Idiopathic Hypersomnia>2 yearsEfficacy phase (II)Investigational MedicinesCost ReimbursementPartially RemoteNeurologyPsychiatry

Localized Ocular Melanoma: IDE196 Treatment Study

We are testing the investigational drug IDE196 to see if it can shrink tumors in patients with localized ocular melanoma before surgery. The study aims to evaluate its safety and effectiveness in improving treatment outcomes.

Uveal MelanomaEfficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesOncologyOphthalmology

Metastatic Uveal Melanoma: IDE196 and Crizotinib Combination

We are studying a new combination treatment for HLA-A2 negative metastatic uveal melanoma to see if it works better than current options. The trial will also evaluate the safety and quality of life for participants.

Uveal Melanoma>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncologyOphthalmology